Page 38 - 2022_02-Haematologica-web

S.E. Karol et al.
Contributions
SEK, WEE, CHP, SJ and MVR conceived and designed the study; KRC, ARM, CC, DP, SEK, HI, JER, MLM, RCR, TAG, JJY, WEE, SJ, CHP, and MVR provided study material or patients and collected and/or assembled data; NMK, YL, JCP, ERF, CAS, WY, CC, YL and DP, analyzed and interpreted data; MVR wrote the first draft of the manuscript; all authors contributed to the revision of the manuscript; and all authors approved the final submitted version of the manuscript.
Acknowledgments
The authors thank the patients and parents who participated in the clinical protocols included in this study, and the participating cli- nicians and research staff.
Funding
This work was supported by National Institutes of Health GM115279, CA35401, CA142665, CA21765, and K08CA250418, and the American Lebanese Syrian Associated Charities. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data-sharing statement
De-identified data used in the preparation of this manuscript are available upon request.
References
1. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana- Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211-1218.
2. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG- asparaginase to reduce asparaginase-associ- ated toxicities: a NOPHO ALL2008 ran- domized study. J Clin Oncol. 2019;37(19): 1638-1646.
3.Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive tri- als in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-284.
4. Smid EJ, Driessen AJ, Konings WN. Mechanism and energetics of dipeptide transport in membrane vesicles of Lactococcus lactis. J Bacteriol. 1989;171(1): 292-298.
5. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10(10): 957-966.
6. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011;118(2):243-251.
7. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adoles- cents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(5):2548- 2555.
8. Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood. 2018;132(4):351-361.
9. Gaynon PS, Steinherz PG, Bleyer WA, et al. Association of delivered drug dose and out- come for children with acute lymphoblastic leukemia and unfavorable presenting fea- tures. Med Pediatr Oncol. 1991;19(4):221- 227.
10. Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome- negative acute lymphoblastic leukaemia: a
single-arm, phase 2 study. Lancet Oncol.
2018;19(2):240-248.
11. Pui CH, Campana D, Pei D, et al. Treating
childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-2741.
12. Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377-3391.
13.Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lym- phoblastic leukemia. Blood. 2012;119(7): 1658-1664.
14.Liu C, Janke LJ, Kawedia JD, et al. Asparaginase potentiates glucocorticoid- induced osteonecrosis in a mouse model. PLoS One. 2016;11(3):e0151433.
15. Merryman R, Stevenson KE, Gostic WJ 2nd, et al. Asparaginase-associated myelo- suppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59(5):925-927. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol. 1997;98(4):945-951.
17.Usami I, Imamura T, Takahashi Y, et al. Discontinuation of L-asparaginase and poor response to prednisolone are associat- ed with poor outcome of ETV6-RUNX1- positive pediatric B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 2019;109(4):477-482.
18. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparagi- nase with Erwinia-asparaginase in the treatment of childhood lymphoid malig- nancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002;99(8):2734-2739.
19. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on out- come in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38(17):1897-1905.
20. Mondelaers V, Suciu S, De Moerloose B, et al. Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC- CLG randomized phase III trial 58951.
Haematologica. 2017;102(10):1727-1738. 21. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36
(7):503-517.
22.Relling MV, Hancock ML, Boyett JM, Pui
16.
25. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermedi- ate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809-818.
26. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with inter- mediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99(3):825-833.
27. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lym- phoblastic leukaemia: a multicentre ran- domised trial. Lancet. 2007;369(9556):123- 131.
28. De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vin- cristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lym- phoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood. 2010;116(1):36-44.
29.Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group pro- tocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646-1654.
23.
24.
CH, Evans WE. Prognostic importance of 6- mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9): 2817-2823.
Bhatia S, Landier W, Hageman L, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lym- phoblastic leukemia: a Children's Oncology Group study. JAMA Oncol. 2015;1(3):287-295.
Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095-1105.
380
haematologica | 2022; 107(2)